International Stem Cell Corp to Present at the Southern California Investor Conference on August 30, 2012

CARLSBAD, CA--(Marketwire - Aug 23, 2012) - International Stem Cell Corporation (OTCQB: ISCO) ( ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, announced today that Dr. Simon Craw, Executive Vice President of Business Development and Investor Relations, will present at the 2012 Southern California Investor Conference on Thursday, August 30, 2012, at 2:30 pm PT / 5:30 pm ET. The conference will be held at the Marriott Hotel in Newport Beach, California.

Southern California Investor Conference
Date: Thursday, August 30, 2012
Time: 2:30 pm PT / 5:30 pm ET
Location: Marriott Hotel, Newport Beach, CA

Please contact the conference organizers if you have an interest in attending these conferences or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email or phone 1-212-301-7130 to arrange a meeting with management.

Conference participation is limited by capacity and registration is required. For more information on the conference, please visit the conference website at

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( More information is available at

To subscribe to receive ongoing corporate communications, please click on the following link:

Safe harbor statement

Statements pertaining to anticipated developments, potential sales growth, new products and distribution channels and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact Information:


International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383

Investor Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone: 212-301-7130